Search

Jing Su

from New York, NY
Get Report
Related to:
Xiaoming M Chen, 63Xiaoyong Yong Yan, 58Ching Chih Pang, 71Lou Xiaobin, 47Xiaoling Sun, 62Tony HsuLucy Hsu
Connected to:
Ae L Su, 71Annabelle L Su, 65Baiya Su, 35Brenda R Su, 30Chelsea J Su, 51Chenyin Su, 38Chi-Hsiang Su, 64Chiahsien Su, 48Chiaoling Su, 48Chienchin Su, 41

Jing Su Phones & Addresses

  • New York, NY
  • Flushing, NY

Resumes

Resumes

Jing Su Photo 1

Associate At Cooper, Robertson & Partners

View page
Position:
Associate at Cooper, Robertson & Partners
Location:
Greater New York City Area
Industry:
Architecture & Planning
Work:
Cooper, Robertson & Partners
Associate
Education:
Massachusetts Institute of Technology 2001 - 2004
S.MArchS, Architecture Massachusetts Institute of Technology 2001 - 2004
MCP, City Planning Tsinghua University 1995 - 2000
B.Arch, Architecture
Jing Su Photo 2

Research Associate At Wake Forest Baptist Health

View page
Position:
Research Associate at Wake Forest Baptist Health
Location:
Winston Salem, North Carolina
Industry:
Research
Work:
Wake Forest Baptist Health since Jan 2013
Research Associate
The Methodist Hospital System Jul 2011 - Jan 2013
Research Associate
The Methodist Hospital Sep 2010 - Jun 2011
Postdoc Research Associate
UMass Amhesrt Feb 2009 - May 2010
Postdoctoral Research Associate
Georgia Institute of Technology Jan 2008 - Feb 2009
Research Assistant
Education:
Emory University 2001 - 2007
Doctor of Philosophy (PhD), Biomedical/Medical Engineering Georgia Institute of Technology 2001 - 2007
PhD, Biomedical Engineering Tianjin University 1997 - 2000
Master, Material
Skills:
Systems Biology
Biomaterials
Molecular & Cellular Biology
Combinatorial Optimization
High Throughput Screening
Photolithography
Genomics
Languages:
English
Chinese
Jing Su Photo 3

Director Of Exploratory Chemistry At Merck

View page
Position:
Director of Exploratory Chemistry at Merck
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Merck since 2011
Director of Exploratory Chemistry
Merck 2008 - 2010
Senior Principal Scientist
Ontogen Inc. 1997 - 1998
Research Scientist
Education:
University of Chicago 1990 - 1995
Ph.D, Chemistry Fudan University
Bachelor of Science (BS), Chemistry
Jing Su Photo 4

Project Coordinator At 1199 Seiu

View page
Position:
Project Coordinator at 1199 SEIU
Location:
Greater New York City Area
Industry:
Hospital & Health Care
Work:
1199 SEIU
Project Coordinator
Jing Su Photo 5

Student At Yale University

View page
Location:
Greater New York City Area
Industry:
Environmental Services
Education:
Yale University 2006 - 2008
Jing Su Photo 6

Trader At Citigroup

View page
Position:
Trader at Citigroup
Location:
Greater New York City Area
Industry:
Investment Banking
Work:
Citigroup since Sep 2005
Trader
Education:
University of Michigan 2003 - 2005
MS, Financial Engineering
Jing Su Photo 7

Scientist At Rma Of Nj

View page
Location:
Greater New York City Area
Industry:
Research
Jing Su Photo 8

Project Coordinator At 1199Seiu Training And Employment Fund

View page
Location:
Greater New York City Area
Industry:
Nonprofit Organization Management

Publications

Us Patents

Mch Antagonists For The Treatment Of Obesity

View page
US Patent:
7348328, Mar 25, 2008
Filed:
Dec 3, 2002
Appl. No.:
10/308782
Inventors:
John W. Clader - Cranford NJ, US
Anandan Palani - Bridgewater NJ, US
Ruo Xu - Watchung NJ, US
Mark D. McBriar - Stewartsville NJ, US
Jing Su - Scotch Plains NJ, US
Haiqun Tang - Belle Mead NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 31/497
C07D 237/02
C07D 265/30
US Classification:
51425212, 544 63, 544224
Abstract:
The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Macrocyclic Inhibitors Of Hepatitis C Virus Ns3-Serine Protease

View page
US Patent:
7592419, Sep 22, 2009
Filed:
Sep 23, 2004
Appl. No.:
10/948367
Inventors:
Srikanth Venkatraman - Woodbridge NJ, US
F. George Njoroge - Warren NJ, US
Wanli Wu - Edison NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US
Brian McKittrick - New Vernon NJ, US
Jing Su - Scotch Plains NJ, US
Francisco Velazquez - Clinton NJ, US
Patrick A. Pinto - Morris Plains NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
A61K 38/12
A61K 38/00
US Classification:
530317, 530323
Abstract:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1:.

Heterocyclyls As Selective Melanin Concentrating Hormone Receptor Antagonists For The Treatment Of Obesity And Related Disorders

View page
US Patent:
7361769, Apr 22, 2008
Filed:
Jul 14, 2005
Appl. No.:
11/181255
Inventors:
Jing Su - Scotch Plains NJ, US
Brian A. McKittrick - New Vernon NJ, US
Haiqun Tang - Belle Mead NJ, US
Li Qiang - Edison NJ, US
Assignee:
Schering Corporation - Kenilworth NJ
International Classification:
C07D 285/08
C07D 27/06
C07D 277/28
C07D 263/48
C07D 249/04
C07D 249/08
C07D 233/56
C07D 231/12
C07D 207/323
C07D 207/325
US Classification:
548128, 548131, 548204, 548236, 548255, 5482676, 5483381, 5483751, 548561, 549 76, 549496
Abstract:
The present invention discloses compounds of formula I.

Macrocyclic Inhibitors Of Hepatitis C Virus Ns3 Serine Protease

View page
US Patent:
20110150835, Jun 23, 2011
Filed:
Oct 31, 2007
Appl. No.:
11/931408
Inventors:
Srikanth Venkatraman - Woodbridge NJ, US
F. George Njoroge - Warren NJ, US
Wanli Wu - East Brunswick NJ, US
Viyyoor M. Girijavallabhan - Parsippany NJ, US
Brian A. McKittrick - New Vernon NJ, US
Jing Su - Scotch Plains NJ, US
Francisco Velazquez - Clinton NJ, US
Patrick A. Pinto - Morris Plains NJ, US
International Classification:
A61K 38/21
C07D 491/044
A61K 31/454
A61K 31/7056
A61K 31/55
A61K 31/496
A61K 31/407
A61K 31/38
A61K 31/541
C07D 487/04
A61K 31/427
A61P 31/14
US Classification:
424 857, 540455, 514322, 424 854, 514 43, 51421204, 51425408, 514414, 514430, 5142282, 540460, 514372
Abstract:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

Modulators Of Protein Tyrosine Phosphatases (Ptpases)

View page
US Patent:
62253298, May 1, 2001
Filed:
Mar 9, 1999
Appl. No.:
9/265069
Inventors:
Lutz Stefan Richter - V.ae butted.rl.o slashed.se, DK
Henrik Sune Andersen - Lyngby, DK
Josef Vagner - V.ae butted.rl.o slashed.se, DK
Claus Bekker Jeppesen - Niv.ang., DK
Niels Peter Hundahl M.o slashed.ller - Copenhagen, DK
Sven Branner - Lyngby, DK
Jing Su - New York NY
Farid Bakir - San Diego CA
Luke Milburn Judge - La Jolla CA
Assignee:
Novo Nordisk A/S - Bagsvaerd
International Classification:
A61K 3141
C07F 906
C07C25500
C07C 6976
C07C 6300
US Classification:
514359
Abstract:
The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTP. alpha. , LAR and HePTP or the like, ##STR1## wherein A, R. sub. 1, R. sub. 2, R. sub. 3, R. sub. 4, R. sub. 16 and R. sub. 17 are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

Benzimidazoles And Indoles As Taro Inhibitors

View page
US Patent:
20210346344, Nov 11, 2021
Filed:
Jul 26, 2021
Appl. No.:
17/385194
Inventors:
- Rahway NJ, US
Ginny Dai HO - Murray Hill NJ, US
Sookhee N. HA - Warren NJ, US
Sandra J. KOSEOGLU - Fanwood NJ, US
Marc A. LABROLI - West Point PA, US
Sang Ho LEE - Berkeley Heights NJ, US
Mihir MANDAL - Westfield NJ, US
Jianping PAN - Monmouth Junction NJ, US
Weidong PAN - Hillsborough NJ, US
Terry ROEMER - Cranford NJ, US
Jing SU - Scotch Plains NJ, US
Christopher Michael TAN - Scotch Plains NJ, US
Zheng TAN - Westfield NJ, US
Hao WANG - Scotch Plains NJ, US
Christine YANG - New Brunswick NJ, US
Shu-Wei YANG - Edison NJ, US
Assignee:
MERCK SHARP & DOHME CORP. - Rahway NJ
International Classification:
A61K 31/397
A61P 31/04
A61K 31/407
C07D 235/08
C07D 401/04
C07D 401/14
C07D 403/04
C07D 403/06
C07D 471/04
Abstract:
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

Oxazolidinones As Taro Inhibitors

View page
US Patent:
20210346364, Nov 11, 2021
Filed:
Jul 26, 2021
Appl. No.:
17/385258
Inventors:
- Rahway NJ, US
Reynalda DE JESUS - East Brunswick NJ, US
Charles J. GIll - Beachwood NJ, US
Ginny Dai HO - Murray Hill NJ, US
Sookhee N. HA - Warren NJ, US
Sandra J. KOSEOGLU - Fanwood NJ, US
Marc A. LABROLI - West Point PA, US
Sang Ho LEE - Berkeley Heights NJ, US
Mihir MANDAL - Westfield NJ, US
Terry ROEMER - Cranford NJ, US
Jing SU - Scotch Plains NJ, US
Christopher Michael TAN - Scotch Plains NJ, US
Zheng TAN - Westfield NJ, US
Haifeng TANG - Metuchen NJ, US
Hao WANG - Scotch Plains NJ, US
Christine YANG - New Brunswick NJ, US
Shu-Wei YANG - Edison NJ, US
Assignee:
MERCK SHARP & DOHME CORP. - Rahway NJ
International Classification:
A61K 31/4439
A61P 31/04
A61K 31/407
A61K 31/421
A61K 31/422
A61K 31/427
A61K 31/431
A61K 31/4375
A61K 31/438
A61K 31/4709
A61K 31/5377
A61K 31/5383
C07D 263/26
C07D 413/04
C07D 413/06
C07D 413/12
C07D 413/14
C07D 417/12
C07D 471/04
C07D 491/048
C07D 495/04
C07D 498/04
Abstract:
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

Oxazolidinones As Taro Inhibitors

View page
US Patent:
20200261436, Aug 20, 2020
Filed:
Dec 13, 2016
Appl. No.:
16/061519
Inventors:
- Rahway NJ, US
Reynalda DE JESUS - East Brunswick NJ, US
Charles J. GIll - Beachwood NJ, US
Ginny Dai HO - Murray Hill NJ, US
Sookhee N. HA - Warren NJ, US
Sandra J. KOSEOGLU - Fanwood NJ, US
Marc A. LABROLI - West Point PA, US
Sang Ho LEE - Berkeley Heights NJ, US
Mihir MANDAL - Westfield NJ, US
Terry ROEMER - Cranford NJ, US
Jing SU - Scotch Plains NJ, US
Christopher Michael TAN - Scotch Plains NJ, US
Zheng TAN - Westfield NJ, US
Haifeng TANG - Metuchen NJ, US
Hao WANG - Scotch Plains NJ, US
Christine YANG - New Brunswick NJ, US
Shu-Wei YANG - Edison NJ, US
Assignee:
MERCK SHARP & DOHME CORP. - Rahway NJ
International Classification:
A61K 31/4439
A61K 31/407
A61K 31/431
C07D 413/12
C07D 471/04
C07D 263/26
C07D 495/04
C07D 491/048
C07D 417/12
C07D 413/14
C07D 413/06
C07D 413/04
C07D 498/04
A61K 31/4709
A61K 31/438
A61K 31/421
A61K 31/4375
A61K 31/422
A61K 31/427
A61K 31/5377
A61K 31/5383
A61P 31/04
Abstract:
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.
Control profile
Jing Su from New York, NY Get Report